Teva Pharmaceutical cash flow strength cuts chances of M&A loan

Israeli generic drugmaker Teva Pharmaceutical’s $6.8bn takeover of US based Cephalon may involve a syndicated loan, although the bond markets and strong internal cash flow are strong potential funding sources, according to loans bankers close to the borrower.

  • 03 May 2011

“They could probably pay for it out of internal cash flow,” said a loans banker close to the borrower. “They have time so they will probably do a bond issue.”

Teva recorded record annual cash flow of $4.1bn for 2010, up from $3.4bn in 2009.

Teva and Cephalon announced the ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

GlobalCapital European securitization league table

Rank Lead Manager/Arranger Total Volume $m No. of Deals Share % by Volume
1 Citi 2,007 6 18.96
2 BNP Paribas 1,434 4 13.55
3 Goldman Sachs 1,392 3 13.15
4 Barclays 1,097 2 10.37
5 Morgan Stanley 1,094 2 10.34

Bookrunners of Global Structured Finance

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 Citi 18,193.54 60 11.52%
2 Wells Fargo Securities 16,128.82 45 10.21%
3 JPMorgan 14,420.48 44 9.13%
4 Bank of America Merrill Lynch 14,370.49 47 9.10%
5 Barclays 10,634.97 35 6.73%